Low LeverageZero reported debt materially reduces near-term refinancing and interest-rate risk, preserving balance-sheet optionality. For an early-stage biotech that will likely need external funding, low leverage keeps borrowing capacity available and lowers insolvency risk versus peers with heavy debt.

Focused R&D PlatformA clear, single-target platform (α10β1) supporting both regenerative orthopedics and oncology creates durable scientific focus and potential pipeline synergies. A shared biomarker can enable reuse of preclinical knowledge, reduce incremental R&D costs and increase odds of multiple product opportunities over time.

Positive Gross Profit In Recent YearsReported positive gross profit in 2024–2025 indicates that core product or service economics can cover direct costs, a structural prerequisite for scalable margins. If operating expenses can be managed while commercialization progresses, this supports a credible path to durable profitability.

Bears Say

High Cash BurnSustained operating cash outflows in the -40M to -53M range over several years create persistent funding needs that drive dilution or dependence on capital markets. This undermines long-term financial independence and increases execution risk if financing conditions tighten.

Negative Shareholders' EquityA negative equity position weakens balance-sheet resilience and limits conventional financing options (debt or equity on favorable terms). It raises structural solvency concerns and reduces flexibility to absorb setbacks or fund multi-year development programs without substantial external support.

Persistent Operating Losses And Volatile RevenueDeep, recurring operating losses and volatile, declining revenue signal weak near-term commercialization traction and high fixed-cost leverage. Over a multi-month horizon this structural profitability gap implies continued reliance on funding and a longer timeline to demonstrate sustainable business economics.

Xintela AB News

1XT Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Xintela AB (1XT) is scheduled to report 4th quarter earnings on 02/27/2026. Regarding Q4 estimates, Wall Street analysts...

26d ago

1XT Upcoming Earnings Report: What to Expect?

Xintela AB (1XT) is scheduled to report 2nd quarter earnings on 08/29/2025. Regarding Q2 estimates, Wall Street analysts...

7M ago

1XT FAQ

What was Xintela AB’s price range in the past 12 months?

Xintela AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.

What is Xintela AB’s market cap?

Xintela AB’s market cap is €17.65M.

When is Xintela AB’s upcoming earnings report date?

Xintela AB’s upcoming earnings report date is May 22, 2026 which is in 60 days.

How were Xintela AB’s earnings last quarter?

Xintela AB released its earnings results on Feb 27, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of >-€0.001 by >-€0.001.

Is Xintela AB overvalued?

According to Wall Street analysts Xintela AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xintela AB pay dividends?

Xintela AB does not currently pay dividends.

What is Xintela AB’s EPS estimate?

Xintela AB’s EPS estimate is >-0.01.

How many shares outstanding does Xintela AB have?

Xintela AB has 861,266,850 shares outstanding.

What happened to Xintela AB’s price movement after its last earnings report?

Xintela AB reported an EPS of -€0.002 in its last earnings report, missing expectations of >-€0.001. Following the earnings report the stock price went down -7.143%.

Which hedge fund is a major shareholder of Xintela AB?

Currently, no hedge funds are holding shares in DE:1XT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Xintela AB

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.